OvaReady: An automated microfluidic oocyte retrieval and denudation device

Autoivf, Inc., Natick MA

Investigators

Abstract

AutoIVF's OvaReady project, supported by Phase-II SBIR funding, introduces a groundbreaking automated microfluidic technology aimed at transforming the In-Vitro Fertilization (IVF) process. By automating the isolation and denudation of Cumulus-Oocyte-Complexes (COCs) from follicular fluid aspirate (FFA), OvaReady seeks to enhance the efficiency, safety, and accessibility of IVF treatments. The technology's novel approach facilitates a one-touch preparation of oocytes for Intracytoplasmic Sperm Injection (ICSI) or cryopreservation within a closed system, minimizing exposure to environmental variations and improving treatment outcomes. This innovation aligns with NICHD's priorities for developing infertility diagnosis and treatment tools in resource-limited settings. OvaReady's immediate impact is demonstrated through increased oocyte recovery and preservation of oocyte quality, addressing the correlation between oocyte quantity and successful IVF outcomes. The system's efficiency has been validated in preliminary studies, revealing its potential to surpass the performance of traditional manual methods. Furthermore, OvaReady's design allows for decentralized IVF services, enabling the collection and preparation of oocytes at satellite clinics, thereby broadening access to fertility treatments. The Phase-IIB project aims to refine OvaReady for commercial and regulatory approval, focusing on ease of use, scaling up production, and developing image processing algorithms for automated oocyte enumeration and classification. This phase will also involve disseminating the technology to major U.S. clinics to gather supportive data. By standardizing the oocyte collection process and lowering barriers to IVF access, AutoIVF envisions OvaReady as a key player in the future of fertility treatments, paving the way for its successful market introduction and adoption. The OvaReady commercialization strategy includes a phased approach to regulatory approval, anticipating a market launch by 2028 and profitability by 2031, with initial emphasis on leading U.S. clinics before expanding to the European market. AutoIVF's vision and innovation, encapsulated in OvaReady, promise to transform IVF by making fertility preservation and treatment more accessible, reliable, and cost-effective, heralding a new era in reproductive healthcare.